- d
Adverse events associated with risdiplam use
- datadryad.org
- data.niaid.nih.gov
- +1more
zipUpdated Mar 13, 2024
Share
Facebook
Twitter
EmailClick to copy linkLink copiedCiteLimei Liu (2024). Adverse events associated with risdiplam use [Dataset]. http://doi.org/10.5061/dryad.573n5tbfvzipAvailable download formatsUnique identifierhttps://doi.org/10.5061/dryad.573n5tbfvDataset updatedMar 13, 2024Dataset provided byDryadAuthorsLimei LiuTime period coveredFeb 14, 2024DescriptionData on risdiplam-related adverse events
https://doi.org/10.5061/dryad.573n5tbfv
We examined incidents reported between the third quarter of 2020 and the second quarter of 2023. The imbalance of risdiplam-related AEs was evaluated by computing the reporting odds ratio. A total of 5,406,334 reports were thoroughly reviewed. By removing duplicate reports, we identified 1588 reports in which risdiplam was the main suspected drug whose use was accompanied by 3470 associated AEs. Among the included AEs, 703 were categorized as serious and 885 as non-serious. Risdiplam use induced AEs across 18 organ systems, resulting in 130 positive signals.
Description of the data and file structure
Table 1 counts the demographic information related to risdiplam;
List of Abbreviations: DEMO, patient demographics; DRUG, administration drug details; REAC, records of adverse events.
Table 2 summarizes the RORs and confidence intervals of the adverse ev...
Not seeing a result you expected?
Learn how you can add new datasets to our index.
FacebookTwitterEmailAdverse events associated with risdiplam use
Data on risdiplam-related adverse events
https://doi.org/10.5061/dryad.573n5tbfv
We examined incidents reported between the third quarter of 2020 and the second quarter of 2023. The imbalance of risdiplam-related AEs was evaluated by computing the reporting odds ratio. A total of 5,406,334 reports were thoroughly reviewed. By removing duplicate reports, we identified 1588 reports in which risdiplam was the main suspected drug whose use was accompanied by 3470 associated AEs. Among the included AEs, 703 were categorized as serious and 885 as non-serious. Risdiplam use induced AEs across 18 organ systems, resulting in 130 positive signals.
Description of the data and file structure
Table 1 counts the demographic information related to risdiplam;
List of Abbreviations: DEMO, patient demographics; DRUG, administration drug details; REAC, records of adverse events.
Table 2 summarizes the RORs and confidence intervals of the adverse ev...